<DOC>
	<DOC>NCT00566761</DOC>
	<brief_summary>Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.</brief_summary>
	<brief_title>Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO</brief_title>
	<detailed_description>Comparison of two groups with different treatment with registrations of outcome in BCVA and complications</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Macular edema secondary to central retinal vein occlusion BCVA worse than 20/40 Central macular &gt;250 mc with OCT Diabetic retinopathy or other retinopathy Media opacity that does not allow following steroid responder diagnosed glaucoma or IOP &gt; 21 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Macular edema</keyword>
	<keyword>central retinal vein occlusion</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>triamcinolone</keyword>
</DOC>